FUZEON

Compare FUZEON  to:
Compare
Compare

Generic Name for FUZEON

Enfuvirtide 90mg/mL; pwd for SC inj after reconstitution; preservative-free.

Legal Classification:

Rx

Pharmacological Class for FUZEON

Fusion inhibitor.

Manufacturer of FUZEON

Roche Laboratories

Indications for FUZEON

Treatment of HIV-1 infection, in combination with other antiretroviral agents, in treatment-experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.

Adult dose for FUZEON

Give by SC inj into upper arm, anterior thigh, or abdomen (not into moles, scar tissue, bruises, or navel). ≥16yrs: 90mg twice daily. Rotate inj sites.

Children's dosing for FUZEON

6–16yrs: limited data available; doses of 2mg/kg (max 90mg) twice daily have been used.

Precautions for FUZEON

Discontinue if hypersensitivity occurs; do not rechallenge. Monitor for pneumonia (esp. if low initial CD4 cell count, high initial viral load, or smoker). Renal insufficiency (CrCl <35mL/min). Supervise 1st dose. Pregnancy (Cat.B). Nursing mothers: not recommended.

Interactions for FUZEON

May cause false (+) ELISA test for HIV.

Adverse Reactions for FUZEON

Inj site reactions, diarrhea, nausea, fatigue, insomnia, infections (eg, bacterial pneumonia), peripheral neuropathy, pancreatitis, hypersensitivity reactions (eg, rash, fever, GI upset, elevated ALT/AST, eosinophilia), lab abnormalities (eg, elevated amylase).

How is FUZEON supplied?

Kit—1 (60 vials w. supplies)

Related Disease:

HIV~antivirals

Related Resources

FDA reviews cardiac risk of Invirase in combination with Norvir

February 23, 2010

The FDA has notified healthcare professionals and patients that it is reviewing clinical trial data about a potentially serious effect on the heart associated with the use of Invirase (saquinavir, from Roche) in combination with Norvir (ritonavir, from Abbott).

Heat-stable Norvir tablets approved

February 16, 2010

The FDA has approved a heat-stable formulation of Norvir tablets (ritonavir, from Abbott) that can be stored at room temperature.

Videx and Videx EC labeling revised to include risk of non-cirrhotic portal hypertension

January 29, 2010

The FDA has notified healthcare professionals and patients that the use of Videx or Videx EC (didanosine, from Bristol-Myers Squibb) may cause non-cirrhotic portal hypertension, a rare but serious complication.

Prezista labeling updated to include 96-week data

January 28, 2010

Tibotec Therapeutics announced that the FDA has approved an updated label for Prezista (darunavir tablets) which includes 96-week data from the ARTEMIS and TITAN studies.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).